Oral Bevacizumab-800CW and Cetuximab-800CW Administration to Detect Early Esophageal Adenocarcinomas

NCT05745857 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Barrett's Esophagus Without Dysplasia
Barrett Oesophagitis With Dysplasia
Esophageal Adenocarcinoma

Interventions

DRUG: Avastin
DRUG: Erbitux
DEVICE: Fluorescence endoscopy and multi-diameter single fiber reflectance/single fiber fluorescence (MDSFR/SFF) spectroscopy

Sponsor

University Medical Center Groningen